Silo Pharma SILO

Silo Pharma, Inc. is a developmental stage biopharmaceutical and cryptocurrency company. The firm concentrates on creating novel therapeutics for conditions with high unmet need such as post traumatic stress disorder, stress induced anxiety, fibromyalgia, Alzheimer’s disease and multiple sclerosis. Its lead program SPC15 is an intranasal serotonin 4 receptor agonist intended for post traumatic stress disorder and stress induced anxiety. Additional candidates include SP26 a ketamine based polymer implant for fibromyalgia, SPC14 targeting Alzheimer’s disease and SPU16 a CNS homing peptide for multiple sclerosis. Parallel to its therapeutic work the company has adopted a cryptocurrency treasury strategy that holds digital assets including Bitcoin, Ethereum, Solana and related staked tokens to generate yield.

Revenue is currently generated through license fees, milestone payments and royalties received under agreements with Columbia University, the University of Maryland Baltimore and Medspray Pharma BV. Under the sponsored research agreement with Columbia University the company committed to pay a total of $1,436,082 over the project period. The agreement with the University of Maryland Baltimore includes an upfront license fee of $75,000 plus potential milestone and royalty payments. The Medspray Pharma BV license calls for a quarterly royalty equal to 5% of net sales of products using its nasal spray technology. As the company has not yet commercialized any product, present income depends on research progress and the achievement of contractual milestones, while future revenue could arise from the sale of SPC15, SP26, SPC14 and SPU16 if they obtain regulatory approval.

Silo Pharma operates in a competitive biopharmaceutical environment where large pharmaceutical, specialty pharma and biotechnology firms have greater financial, technical and human resources. The company seeks to carve a niche by focusing on psychedelic based treatments and innovative drug delivery systems such as intranasal formulations and polymer implants. Its collaborations with Columbia University and the University of Maryland Baltimore provide access to proprietary technology and intellectual property that may serve as barriers to entry for rivals. The firm also emphasizes a 505(b)(2) regulatory pathway for several candidates which could reduce development time and cost compared to traditional new drug applications. Despite limited scale the company believes its targeted approach to underserved CNS conditions offers differentiation in a crowded market.

The company’s customer base includes research institutions such as Columbia University and the University of Maryland Baltimore. Licensing partners like Medspray Pharma BV provide technology and receive royalties on future sales. Ultimately the firm aims to serve patients suffering from post traumatic stress disorder, stress induced anxiety, fibromyalgia, Alzheimer’s disease and multiple sclerosis. Healthcare providers such as hospitals, clinics and specialty treatment centers would be the channels through which its therapies reach those patients. The company also envisions serving specific populations like veterans and first responders who experience high rates of stress related disorders.